Despite a recent phase III ECHO-301 trial (NCT02752074) of PD-1 inhibitor in combination with an IDO1 inhibitor in metastatic melanoma showed no significant clinical benefit in the treatment group (pembrolizumab + epacadostat) compared with the control group (pembrolizumab + placebo) [51]. This evidence concerns the gene IDO1 and metastatic melanoma.